LONDON--(BUSINESS WIRE)--e-Therapeutics plc (AIM: ETX), the drug discovery and development company, today announces its interim results for the six months ended 31 July 2012.
(*Events since the end of the period; **announced today)
Lead cancer drug ETS2101 enters clinic
• US phase I trial initiated in patients with brain cancer
• UK phase I trial begins in patients with solid tumours*
• First data expected Q4 2012; final results from brain cancer trial Q4 2013 and solid tumour trial Q1 2014**